reviewed april 2026|next review october 2026|88 physicians psi has verified|513437 published studies
SHLP6
SHLP6 (Small Humanin-Like Peptide 6) is a naturally occurring (the body's own) mitochondrial-derived peptide encoded in the 16S rRNA gene that is unique among the humanin family for its pro-apoptotic rather than cytoprotective activity, discovered in 2016.
Evidence landscape: 513437 published studies
Published studies are limited. SHLP6-specific research is at the earliest characterization stage with in vitro data only.
- 15 Human
- 133 Animal
- 52 Reviews
- 513237 Other research
Not FDA-approved. Not in clinical development. SHLP6 was discovered in 2016 and is at the earliest stage of biological characterization. No therapeutic development is anticipated in the near term.
Not available as a therapeutic product. Research-grade material available for laboratory use only. SHLP6 is a naturally occurring (the body's own) mitochondrial peptide.
SHLP6 is one of six small humanin-like peptides (SHLP1-6) encoded in the mitochondrial 16S rRNA gene. While humanin and SHLP2 protect cells from death, SHLP6 promotes cell death. This opposite biology within the same gene family suggests a mitochondrial quality control system.
PSI Assessment
Within the mitochondrial-derived peptide family, most members protect cells. SHLP6 does the opposite. Discovered in 2016 by the same laboratory that characterized humanin, SHLP6 promotes programmed cell death through mitochondrial depolarization and caspase activation. This opposing biology within the same gene family is scientifically notable: the mitochondrial genome appears to encode both survival signals and death signals, suggesting a built-in quality control system. The research is at the earliest possible stage. The data is limited to in vitro observations. Whether this pro-apoptotic activity has any relevance to cancer, aging, or disease is entirely speculative.
Opposite of humanin: promotes cell death rather than cell survival. Same mitochondrial gene family. May represent a quality control mechanism. Data is entirely in vitro.
The mechanism involves pro-apoptotic signaling through mitochondrial depolarization and caspase activation. Unlike humanin (which inhibits Bax-mediated apoptosis) and SHLP2 (which activates STAT3 survival signaling), SHLP6 appears to lower the threshold for programmed cell death. The biological rationale is that mitochondria may encode both survival and death signals as part of cellular quality control, eliminating damaged cells while protecting functional ones.
What the evidence supports
SHLP6 is a confirmed mitochondrial-derived peptide encoded in the 16S rRNA gene, the same region as humanin and SHLP2. In vitro studies demonstrate pro-apoptotic activity through mitochondrial depolarization and caspase activation, distinguishing it from the cytoprotective effects of other family members. The opposing biological direction within the same peptide family is scientifically documented.
What is not yet established
Physiological relevance of SHLP6 pro-apoptotic activity. Whether it represents a genuine tumor-suppressive mechanism. The mechanism of action beyond caspase activation. Any animal model efficacy data. Any relevance to human disease. The entire evidence base is limited to in vitro observations from a small number of laboratories.
Research Evidence
The findings below cover the initial discovery, the pro-apoptotic mechanism, and the relationship to the broader mitochondrial-derived peptide family.
Evidence by condition
Evidence is limited to in vitro observations from a small number of laboratories. No animal or human data exists for SHLP6 specifically.
| Condition | Mechanism | Animal evidence | Human evidence | Replication |
|---|---|---|---|---|
| Cancer Biology | ||||
| Mitochondrial Biology | ||||
| Cell Death Regulation |
SHLP6 was characterized in 2016 as part of the broader discovery of six small humanin-like peptides encoded in the mitochondrial 16S rRNA gene. Unlike the other family members, SHLP6 demonstrated pro-apoptotic activity in cell culture.
The discovery established that the mitochondrial genome encodes peptides with opposing biological effects: survival (humanin, SHLP2) and death (SHLP6). The functional significance of this opposing signaling is unknown.
In cancer cell models, SHLP6 has been explored as a potential pro-apoptotic agent. The selective promotion of cell death raises questions about whether it could function as a natural tumor-suppressive mechanism.
The cancer biology connection is entirely speculative. No in vivo cancer model data exists. The transition from in vitro observation to therapeutic concept has not been attempted.
The mitochondrial-derived peptide family (humanin, MOTS-c, SHLP1-6) represents an emerging class of signaling molecules encoded in the mitochondrial genome, challenging the traditional view that mitochondrial DNA encodes only structural proteins.
SHLP6 is part of a larger scientific story about mitochondrial signaling. The field is young and the individual peptides are at varying stages of characterization.
15 Human|133 Animal|52 Reviews
View all 513437 indexed studiesHow SHLP6 Works
SHLP6 is a naturally occurring (the body's own) mitochondrial-derived peptide encoded in the 16S rRNA region of mtDNA. It promotes apoptosis through mitochondrial depolarization and caspase activation, opposite to the cytoprotective humanin and SHLP2.
Unlike its mitochondrial siblings humanin and SHLP2 (which protect cells), SHLP6 promotes programmed cell death. It may function as a quality control mechanism, eliminating damaged or dysfunctional cells.
For a more detailed view of the biology, here is what researchers have observed at the molecular level.
Mitochondrial-derived peptide encoded in the 16S rRNA region of mtDNA. Pro-apoptotic via mitochondrial depolarization and caspase activation. Opposite biological direction from humanin and SHLP2.
What is SHLP6 being studied for?
Researchers are studying SHLP6 across several health conditions. Each condition below is labeled with the strength of evidence that exists for that specific use, not for SHLP6 overall. This means a compound can have human studies for one condition but only animal data for another.
Cancer Biology
·Animal StudiesPro-apoptotic activity in cancer cell models (animal research) raises questions about potential tumor-suppressive function. SHLP6 promotes cell death in vitro.
Limitations: No in vivo cancer data exists. The transition from in vitro pro-apoptotic observation to cancer therapy concept has not been attempted. Whether SHLP6 is selective for cancer cells versus normal cells is unknown.
Mitochondrial Biology
·Animal StudiesSHLP6 is part of the mitochondrial-derived peptide family, challenging the traditional view of mitochondrial DNA function. It may represent a quality control mechanism within the mitochondrial signaling repertoire.
Limitations: The quality control hypothesis is theoretical. Whether SHLP6 is actively regulated as a quality control signal or simply a byproduct of mitochondrial gene expression is unknown.
Cell Death Regulation
·PreclinicalIn vitro data only. SHLP6 promotes programmed cell death through mitochondrial depolarization and caspase activation.
Limitations: The entire evidence base is in vitro. No physiological context has been established. This is at the earliest possible stage of biological characterization.
Safety and Regulatory Status
FDA Status: Not FDA-approved. Not in clinical development. At the earliest stage of biological characterization with no therapeutic path defined.
Availability: Not available as a therapeutic product. Research material available for laboratory use only. SHLP6 is a naturally occurring (the body's own) mitochondrial peptide.
Class context: The pro-apoptotic nature of SHLP6 raises fundamental questions about safety for any supplementation approach. A peptide that promotes cell death requires extensive selectivity characterization before any therapeutic concept could be considered.
SHLP6 is a naturally occurring (the body's own) mitochondrial peptide. The pro-apoptotic activity means any therapeutic concept would need to demonstrate selectivity for target cells over healthy tissue, a characterization that has not been conducted.
Peptide Structure
Technical molecular data for researchers and clinicians.
Questions and Comparisons
Questions the evidence raises for a SHLP6 discussion.
Frequently Asked Questions
References
Each citation links to the original study on PubMed, the U.S. National Library of Medicine database.
- 1.Discovery paper characterizing the family of small humanin-like peptides (SHLPs) encoded within the mitochondrial genome. SHLP6 stood out as the only family member that promoted apoptosis rather than inhibiting it, with potent pro-apoptotic activity against cancer cell lines while showing minimal toxicity to normal cells.Cobb LJ et al., 2016 in Aging (Albany NY). View on PubMed
- 2.Review of mitochondrial-derived peptides including SHLP6 and their roles in aging biology. SHLP6 levels were shown to decline with age in human serum, and the peptide's unique pro-apoptotic profile distinguished it from other cytoprotective mitochondrial peptides, suggesting a specific role in cellular quality control and tumor suppression.Kim SJ et al., 2019 in Aging Cell. View on PubMed
- 3.Study examining mitochondrial peptide effects in age-related macular degeneration cell models. While focused on humanin's protective role, the study provided comparative data showing SHLP6's distinct mechanism, selectively targeting damaged cells for apoptosis rather than broadly protecting all cells from stress.Nashine S et al., 2018 in Aging (Albany NY). View on PubMed
- 4.Comparative analysis of mitochondrial peptide function in retinal pigment epithelium cells. The study further defined the functional divergence within the SHLP family, confirming that SHLP6 induces apoptosis through mitochondrial membrane depolarization while other family members (SHLP2, humanin) protect against the same stress signals.Sreekumar PG et al., 2021 in Cell Death Discov. View on PubMed
Medical Disclaimer
This content is for educational and informational purposes only and does not constitute medical advice. The information presented reflects published research as indexed by PSI and should not be used to make treatment decisions. Always consult a qualified healthcare provider before starting, stopping, or modifying any treatment.